Merck & Co., Inc. has outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation, with the company aiming to provide innovative and distinctive products and services while satisfying customer needs and creating long term shareholder value. 

The new Merck is strong and better equipped than before, and has a broadened, diversified portfolio of innovative medicines and vaccines, and products for consumer and animal health, said Richard Clark, chairman, president and chief executive officer of Merck. 

From the outset, Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines and animal and consumer health products. This portfolio is complemented by a robust pipeline with more than 15 promising late-stage candidates spanning critical therapeutic categories. Merck now has approximately 106,000 employees and operates in more than 140 countries around the world, including emerging markets. The company expects to generate more than 50 percent of its revenue outside the US. 

 
The company's corporate headquarters will be in Whitehouse Station, New Jersey. In addition, the company's US organisation for the Global Human Health division and Merck Research Laboratories will be headquartered in Upper Gwynedd, Pennsylvania. The former Schering-Plough headquarters in Kenilworth, New Jersey and Merck's operations in Rahway, New Jersey, will continue to be important sites, with large and diverse operations encompassing marketing, manufacturing and research.  

At this time, all other sites will continue to operate as they did before the merger.

The new Merck has a broad portfolio of medicines driven in part by the addition of valuable products with long periods of exclusivity. By leveraging Merck's expanded product offerings, the company expects to benefit from additional revenue growth opportunities. 

The new Merck's expanded portfolio also includes leading products from its Animal Health and Consumer Health Care business units.

With the merger complete, Merck will take a global approach to unify and simplify use of its trade name. The company will use the trade name 'Merck' in the US and Canada and elsewhere use the trade name 'MSD.'